NeuroVive Raises $3 Million for Taiwan Subsidiary; Plans IPO

NeuroVive, a Swedish clinical-stage pharma focused on drugs that protect mitochondrial function, established a subsidiary in Taiwan and raised $3.3 million for the venture. The company previously announced it would IPO the new company, NeuroVive Pharmaceutical Asia, Inc., on the Taiwan stock exchange. NeuroVive Asia holds the Asian rights (ex-China) to NeuroVive's two clinical stage projects, which address cerebral-cardiovascular problems. In 2012, NeuroVive out-licensed China rights for the drugs to Sihuan Pharma. More details.... Stock Symbols: (STO: NVP) (HK: 0460) Share this with colleagues: // //